Is Ozempic Similar to Wegovy — and Does the Difference Matter?

Step 1: Understand what they share and where the similarities end

A question our prescribers hear most weeks is some version of this: "Ozempic and Wegovy are the same drug, so why does it matter which one I ask about?" The chemistry is genuinely close. Both are once-weekly subcutaneous injections of semaglutide, a GLP-1 receptor agonist that works by mimicking a gut hormone released after eating. It slows gastric emptying, reduces appetite signals in the brain, and helps regulate blood sugar. The mechanism is shared. The molecule is shared.

Where they diverge is in licensing and dose. Ozempic is approved in the UK at doses up to 1mg weekly for type 2 diabetes. Wegovy's maintenance doses run higher, 2.4mg per week under the original schedule, and up to 7.2mg with the newer pen the MHRA approved in April 2026. That higher dose is where the clinically meaningful weight-loss results come from. The NHS semaglutide medicines page clearly distinguishes the two by indication. Same molecule, different authorised purpose, different dose ceiling.

There is also a newer development worth knowing: Wegovy tablets (oral semaglutide for weight management) were approved by the MHRA in June 2026, making the UK the first country in Europe to licence an oral GLP-1 medicine for weight loss. The injection and the tablet are distinct products within the same family; the tablet schedule runs 1.5mg, 4mg, 9mg up to 25mg daily.

Step 2: Recognise that UK licensing controls what can legitimately be prescribed for weight loss

The MHRA is the UK medicines regulator, and its licensing decisions are not administrative formalities, they define what a medicine may legally be prescribed for in a standard clinical setting. Ozempic's UK licence covers type 2 diabetes. Wegovy's covers weight management. Those are separate products, even though the active ingredient is the same.

NICE has appraised each product separately and reached different conclusions. Wegovy (semaglutide for weight management) received its NICE recommendation in 2023 under Technology Appraisal TA875, which sets out the conditions under which NHS commissioners should fund it. No equivalent NICE weight-management appraisal exists for Ozempic, because Ozempic has not been submitted or licensed for that purpose. If you see someone online offering Ozempic as a weight-loss treatment, that is a clinical and legal red flag, not a shortcut.

For an in-depth look at how semaglutide works across its different branded forms, our page on semaglutide as a medicine covers the pharmacology in plain language.

Step 3: Know what IS licensed for weight loss, and what the evidence shows

Two injectable treatments are currently licensed in the UK for weight management in adults: Wegovy (semaglutide) and Mounjaro (tirzepatide). Wegovy's pivotal STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. Mounjaro, a dual GIP and GLP-1 receptor agonist, produced larger average reductions in trials (around 20 to 21% at its highest dose) and is the only dual-agonist weight-loss medicine licensed in the UK.

Both require a prescription following a clinical assessment. Neither can be accessed without one from a legitimate, GPhC-registered pharmacy. If you are wondering about Wegovy's place in UK weight management, our overview covers eligibility, how titration works and what to expect from treatment, including what to do when you reach your goal weight on Wegovy, which is a question worth thinking about before you start.

If cost is part of your thinking, it is worth reading about what drives Wegovy pricing in the UK private market before making a decision, the headline figure rarely includes everything a legitimate prescription involves.

For anyone weighing up the options between the two licensed medicines, the weight-loss treatments overview at nume sets out both clearly, so you can go into a consultation with a clearer sense of what questions to ask.

Step 4: How to access a licensed weight-loss medicine through a regulated UK pharmacy

If you are eligible for weight management treatment, the route starts with a clinical consultation. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber (a real clinician reading your answers, not automated software) usually the same day. There is no referral and no waiting list, though clinical suitability determines everything.

Our prescribers review your full picture: BMI, relevant health history, any medicines you already take (some interact with semaglutide or tirzepatide), and your goals. Only after that assessment does a prescription decision follow. If you would like to understand the broader landscape of medicines similar to semaglutide, that page explains where the different GLP-1 options sit relative to each other.

It is also worth knowing that the relationship between Ozempic and semaglutide confuses a lot of people, you are not alone in asking, and the answer has practical consequences for which prescription a clinician can legitimately write.

Speak to our prescribers through a free consultation at our weight-loss treatments page if you would like a clinical assessment for licensed weight management treatment.